Moxiquest 18.92 mg/g Oral Gel for Horses & Ponies

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)

Aktīvā sastāvdaļa:

Moxidectin

Pieejams no:

Zoetis UK Limited

ATĶ kods:

QP54AB02

SNN (starptautisko nepatentēto nosaukumu):

Moxidectin

Zāļu forma:

Oral gel

Receptes veids:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Ārstniecības grupa:

Horses

Ārstniecības joma:

Endectocide

Autorizācija statuss:

Expired

Autorizācija datums:

2012-07-18

Produkta apraksts

Revised: June 2014
AN: 01740/2013
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Moxiquest 18.92 mg/g Oral Gel for Horses & Ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 g contains:
ACTIVE SUBSTANCE:
Moxidectin
18.92 mg
EXCIPIENTS:
Benzyl alcohol
37.84 mg
Disodium Edetate
0.24 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral gel
Yellow gel
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Horses and ponies.
4.2.
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The veterinary medicinal product is indicated for treatment of
infections caused
by moxidectin sensitive strains of:
Large strongyles:

_Strongylus vulgaris_ (adults and arterial stages)

_Strongylus edentatus_ (adults and visceral stages)

_Triodontophorus brevicauda_ (adults)

_Triodontophorus serratus_ (adults)

_Triodontophorus tenuicollis _ (adults)
Small strongyles (adults and intraluminal larval stages):

_Cyathostomum _spp.

_Cylicocyclus _spp_._

_Cylicostephanus _spp_._

_Cylicodontophorus_ spp.

_Gyalocephalus _spp.
Ascarids:

_Parascaris equorum_ (adult and larval stages)
Revised: June 2014
AN: 01740/2013
Page 2 of 5
Other species:

_Oxyuris equi _(adult and larval stages)

_Habronema muscae _(adults)

_Gasterophilus intestinalis _(L2, L3)

_Gasterophilus nasalis _(L2, L3)

_Strongyloides westeri _(adults)

_Trichostrongylus axei_
The veterinary medicinal product has a persistent efficacy of two
weeks against
small strongyles. The excretion of small strongyles eggs is suppressed
for 90
days.
The veterinary medicinal product is effective against (developing)
intramucosal
L4 stages of small strongyles. At 8 weeks after treatment, early
(hypobiotic) EL3
stages of small strongyles are eliminated.
4.3.
CONTRAINDICATIONS
Do not administer to young foals less than 4 months.
Do not administer in cases of known hypersensitivity to the active
ingredient or
to any other milbemycins and to any other ingredients of the
veterina